Differential Gene Expression Analysis of Carboplatin Treatment for Oral Squamous Cell Carcinoma
Department of Stomatology, The Second Hospital of Tianjin Medical University, Tianjin 300211, 1Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, School of Basic Medical Sciences, Tianjin Medical University, 2Department of Stomatology, Tianjin Women’s and Children’s Health Centre, Tianjin 300070, China
Tingting Li, Department of Stomatology, Tianjin Women’s and Children’s Health Center, Tianjin 300070, China, E-mail: email@example.com
Based on the unclear pathological mechanism as well as adverse events following carboplatin treatment, in this study, we developed a comprehensive differential gene profile for oral squamous cell carcinoma patients treated with cisplatin. The messenger ribonucleic acid sequencing data as well as micro ribonucleic acid sequencing data of oral squamous cell carcinoma patients treated with/without carboplatin from two datasets (The Cancer Genome Atlas and hospital) were compared using differential expression analysis; the micro ribonucleic acid-messenger ribonucleic acid’s network was constructed; the functions of potential hub genes were verified with external clinical patient. Compared with untreated group, the carboplatin treated patients showed 123 differentially expressed messenger ribonucleic acids, including 96 up-regulated messenger ribonucleic acids and 27 down-regulated messenger ribonucleic acids. Meanwhile, 12 differential micro ribonucleic acids (Homo sapiens (human)-micro ribonucleic acid-514, human micro ribonucleic acid- 7974 as well as human-micro ribonucleic acid-509 as primary ones) were significantly different between two treatments. The functions and the pathological mechanism of carboplatin treatment were analyzed by quantitative real-time polymerase chain reaction and Western blotting methods. This integrated study hypothesized a micro ribonucleic acid dependent signaling pathway for carboplatin function and provided a beneficial reference for better evaluation of the popularly utilized chemotherapeutic drug.